Natus Medical Director Sells $456,638 in Stock (BABY)
Natus Medical (NASDAQ:BABY) Director Doris Engibous sold 33,750 shares of the stock on the open market in a transaction dated Thursday, September 12th. The shares were sold at an average price of $13.53, for a total value of $456,637.50. Following the transaction, the director now directly owns 6,000 shares in the company. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on BABY shares. Analysts at Zacks downgraded shares of Natus Medical (NASDAQ:BABY) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, July 10th. They now have a $12.40 price target on the stock. Separately, analysts at Roth Capital cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have an “outperform” rating on the stock.
Shares of Natus Medical (NASDAQ:BABY) traded up 3.20% on Tuesday, hitting $13.85. 119,024 shares of the company’s stock traded hands. Natus Medical has a 1-year low of $9.65 and a 1-year high of $15.18. The stock’s 50-day moving average is $13.52 and its 200-day moving average is $13.45. The company has a market cap of $414.9 million and a price-to-earnings ratio of 38.34.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.14 by $0.07. The company had revenue of $82.30 million for the quarter, compared to the consensus estimate of $83.50 million. During the same quarter last year, the company posted $0.12 earnings per share. Natus Medical’s revenue was up 34.9% compared to the same quarter last year. Analysts expect that Natus Medical will post $0.79 EPS for the current fiscal year.
Natus Medical Incorporated (NASDAQ:BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.